Neoadjuvant chemotherapy for borderline resectable and resectable pancreatic adenocarcinoma: single agent gemcitabine may not be inferior to multi-agent chemotherapy. (September 2018) - Kizy, S.; Altman, A.; Hui, J.Y.C.; Tuttle, T.; Marmor, S.; Lou, E.; Greeno, E.; Chang, K.; Denbo, J.W.; Jensen, E.